

Molecular Detection Of Localized Cutaneous Leishmaniasis (Lcl) Among Iraqi Patients Using Real Time-Pcr

Nuha Qasim Mohammed^{1*}, Alaa Mohammed Abidalrizaq Al-khafaji²

^{1*}Veterinary Medicine Collage, University of Al-Qadisiyah, Iraq. Email: nuha.allban@qu.edu.iq

²Veterinary Medicine Collage, University of Al-Qadisiyah, Iraq.

Abstract

The current work highlights the use of a molecular technique to identify the etiological agent of localized cutaneous Leishmaniasis (*Leishmania* spp. parasites) in Iraqi patients with clinical manifestations of suspected Leishmaniasis. Twelve participants were recruited for this study between January 2021 and June 2021 at Baghdad hospital's external clinics. According to the manufacturer's instructions, the acquired samples in the form of skin biopsies were directly treated to a DNA isolation technique employing total DNA using the GeneJET Genomic DNA purification kit. Real-time polymerase chain reaction (real-time –PCR) was used to confirm the presence of *Leishmania* spp. in the twelve samples. Eight of twelve DNA samples (8/12= 66.66%) were positive for the *Leishmania* suspect pathogen, as determined by positive real-time PCR results. The current findings support the ability of the molecular detection approach used in this work to detect and confirm the presence of *Leishmania* spp. pathogen in cutaneous Leishmaniasis in a quick, accurate, specific, and sensitive manner.

Keywords: Localized cutaneous leishmaniasis (LCL), Real time-PCR, *Leishmania* spp., *Leishmania* specific primer, clinical manifestations

Introduction

Leishmaniasis, a parasitic disease, which is classified as a neglected tropical disease (NTD). Leishmaniasis, a neglected tropical disease (NTD), is a parasitic disease caused by the infection with *Leishmaniaspp.* parasites. It is considered a tropical and subtropical aliment. The causative agents *Leishmania* spp. are categorized as intracellular parasites. It was reported that the mode of transmission of leishmaniasis is through the bite of the sand fly *Phlebotomus* and *Lutzomyia* in different regions all over the world (i.e., Northern Africa, the Middle East, Europe, Asia, and part of South America). (Vera-Izaguirre et al., 2006). According to WHO (World Health Organization) records, over 20 *Leishmania* species are the causative agents of leishmaniasis. Additionally, over 90 sandfly species

are reported to be the vehicle of the Leishmania parasites. The WHO website stated that there are 3 main forms of the disease: cutaneous leishmaniasis (CL), visceral leishmaniasis (VL), and mucocutaneous leishmaniasis (MCL). Cutaneous leishmaniasis is the utmost popular type of leishmaniasis and does cause skin lesions, mostly ulcers, on the unprotected portions of the body, resulting in generation of life-long scars (Centre for Disease Control and prevention (CDC) records: https://www.cdc.gov/parasites/leishmaniasis/gen_info/faqs.html).

The cutaneous leishmaniasis is further subdivided into two subgroups: localized cutaneous leishmaniasis (LCL) and diffused cutaneous leishmaniasis (DCL) (Torres-Guerrero et al., 2017). At most, the clinical characteristics include a broad spectrum of manifestations of variable severity that mainly rely on the species of Leishmania implicated and the host immune response (Andrade-Narváez et al., 2001). For instance, in Mexico, the utmost distinctive feature is the cutaneous-chondral form synonymously named "chiclero's ulcer" (Reithinger et al., 2007).

Approximately 95% of CL patients happen in the Mediterranean basin, Americas, the Middle East and Central Asia. In 2019 over 87% of new cases with CL happened in 10 countries: Afghanistan, Brazil, Colombia, Iraq, Iran, Pakistan, the Syrian Arab Republic, Tunisia, Algeria, and Libya. It is predicted that between 600 000 to 1 million novel cases happen throughout the world yearly (<https://www.who.int/news-room/fact-sheets/detail/leishmaniasis>).

According to the wording stated by International Association for Medical Assistance to Travelers (IAMAT) (<https://www.iamat.org/country/iraq/risk/leishmaniasis>), leishmaniasis is prevalent in Iraq. Cutaneous leishmaniasis (CL) makes up nearly 2/3 of cases whilst visceral leishmaniasis (VL) does account for 1/3 of cases. The season with high incidence and prevalence of leishmaniasis begins in May. At present, the ailment remains to do spread in the south region of the Qadisiyah province, approximately 130 kilometers south of Baghdad as a consequence of the increase in the Sandfly activity. Hence, the transmission of leishmaniasis illness in Iraq is in a continuous elevation.

The goal of the present study is to monitor the prevalence of LCL cases in Iraq in a small sample size of 12 cases using a molecular approach: real-time PCR using a leishmania specific primer set, in the context of alarm records generated by WHO and CDC regarding the current status of leishmaniasis all over the world and particularly in Iraq.

Materials and methods

Ethical statement

The investigation was approved by the national center for tropical and zoonotic diseases in Baghdad, Iraq. An informed written consent was signed prior to sample collection from the enrolled patients in this study. The written consents were signed directly by the adult participant or the parents in case of children participants.

Study participants and study sites

Twelve patients were enrolled in this study. The study participants included both genders. Moreover, the recruited patients included two categories according to their ages: adults and children. The patients were chosen from those who were accustomed to visit the external clinics in Baghdad hospital.

Clinical manifestations of leishmaniasis

Leishmania imposes a range of cutaneous disease. The spectrum of clinical index might be due to changeability in the virulence of the parasitic etiological agent (and other inherent features). At most, mucosal leishmaniasis (ML) and leishmaniasis recidivans (LR) are caused by oligoparasitic disease related to a distinct cellular immune response. The center of the spectrum includes localized cutaneous leishmaniasis (LCL), which is the most popular clinical demonstration. At the counterpart end of the spectrum, diffuse cutaneous leishmaniasis (DCL) is driven by polyparasitic disease with a prevalence of parasitized macrophages without granulomatous inflammation. This range of clinical presentation and host immune response are like to the clinical presentations in cases suffered from leprosy (Convit et al., 1993).

The clinical manifestations of suspect cutaneous leishmaniasis were diagnosed and described by the physician. A file record for each patient was built up at first visit of the patient to the external clinic in Baghdad hospital.

Collection of clinical specimens

Biopsy samples from skin (4-mm) were collected from patients with suspected leishmaniasis by the aid of local anesthesia using a sterile scalpel in order to do a split in the utmost inflamed border of the most new lesion. Then the gathered biopsy samples were immersed in 200 μ L of transport buffer (10 mM Tris-HCl, pH 8.0 and 10 mM EDTA), followed by incubation at 65 °C for 3 hrs. Storage of samples was performed for 48-72 hrs at 4 °C. After that, the freezing was done for the samples until being used further.

DNA isolation from biopsy samples

All frozen biopsy samples were thawed and were subjected to DNA isolation protocol using the GeneJET genomic purification kit (Thermo Fisher Scientific Co., USA).

Quality and quantity of isolated total DNA

The isolated total DNA from each biopsy sample was run in 1% agarose gel electrophoresis using DNA submarine unit (Clever Co., UK) to assess its quality. After electrophoresis termination, the agarose gel was visualized under UV-transilluminator. On the other hand, the absorbance of the isolated DNA was measured at 260 and 280 nm using Nano-drop Spectrophotometer to assess its quality and quantity. A ratio of > 1.8 of Ab 260/Ab280 indicated good quality of the isolated DNA. The isolated DNA was stored at -20 °C until being processed.

Real time –PCR using *Leishmania* spp. specific primer

The DNA isolated from biopsy samples was subjected to real time –PCR using the *Leishmania* spp. specific primer set : 13A (5'-GTGGGGGAGGGGCGTTCT) and 13B (3'-TTGACCCCAACCACATTATA) to amplify a partial fragment of the genomic DNA of *Leishmania* spp. of 120 bp (Aviles et al., 1999). The PCR mixture contained 50 ng total biopsy DNA, 25 µL SYBR™ Green PCR Master Mix (Thermo Fisher Scientific Co., USA), 0.3 µM of each forward and reverse primer, and the volume was completed to 50 µL using nuclease free water. Then all reaction mixtures were carried out in Rotor Gene 5-Plex (Qiagen, USA). The real time-PCR conditions were settled to be 94 °C for 10 min (initial denaturation), 40 cycles (each cycle: 94 °C for 15 s (for denaturation), 60 °C for 60 s (annealing, extension, and fluorescence acquisition), and 55-95 °C hold for melting. After termination of the real time-PCR run, data collected from reaction mixtures was analyzed for evaluating the melting curve and obtaining the Ct value for each reaction. The expected melting temperature of the PCR product (T_m) displayed in the melting curve was spanned from 81-82 °C. The melting curve with single peak indicated the specificity of the primer and the precision of the data output.

Results

Clinical manifestations of patients with suspect cutaneous leishmaniasis

The clinical manifestations of the suspect cutaneous leishmaniasis demonstrated by the patients enrolled in this study were represented in Figure 1. As shown, the lesion of suspect cutaneous leishmaniasis was exhibited in different regions: face, elbow, and arm. The clinical manifestation were typical cutaneous leishmaniasis with skin lesions (developed after several weeks or months after infection) and swollen

glands. The lesions, with closed or open sores appearance, changed overtime in size and form. The skin lesions were not painful unless there was a bacterial infection.



Figure 1: Representative examples of some patients enrolled in this study with cutaneous leishmaniasis. **A:** clinical manifestation of cutaneous leishmaniasis in the face of a child patient. **B:** clinical manifestation of cutaneous leishmaniasis from an adult patient in the elbow region. **C:** clinical manifestation of cutaneous leishmaniasis from an adult patient in the arm.

Molecular detection of *Leishmania* spp. etiological agent in suspect cutaneous Leishmaniasis DNA biopsy samples

As mentioned previously in the section of materials and methods, the twelve patients with suspect cutaneous leishmaniasis were subjected to real time-PCR experiment using *Leishmania* spp. specific primer set 13A and 13B. Data revealed that 8 out of 12(8/12= 66.66%) DNA biopsy cutaneousleishmaniasis samples proved to have the etiological agent *Leishmania* spp. (Figure 2). The amplification curves depicted in Figure 2 reflected different PCR reactions with different Ct values. Real time-PCR with late Ct values indicated low concentration of the *Leishmania* DNA included in these samples. Conversely, high Ct values in Real time-PCR evidenced high concentration of the *Leishmania* DNA included in these samples (Table 1). Moreover, the melting curves depicted in Figure 3 revealed a single peak in each Real time PCR that reflected the specificity of the *Leishmania* specific primer set used in this study. Additionally, all obtained melting curves from all Real time-PCR showed overlapped peaks that would provide additional evidence about the specificity of the used primer set.




Figure 2: Amplification curves of eight Real time-PCR conducted by 50 DNA biopsy cutaneous Leishmaniasis samples.

Table 1: Ct values of Real time-PCR conducted for 8 DNA biopsy cutaneous leishmaniasis samples.

Sample code	Ct value*
1	28.46
2	28.71
3	28.34
4	31.68
5	22.09
6	25.54
7	28.16
8	28.04

- Ct value: Threshold cycle number at which the first significant luorescence above the background was detected.




Figure 3: Melting curves showing overlapped single peaks from eight Real time –PCR conducted with eight DNA biopsy cutaneous leishmaniasis samples.

Discussion

Cutaneous leishmaniasis (CL) is the most popular form of leishmaniasis and has a predestined 1.5 million infections annually worldwide (Desjeux 2004). This disease prevalently does occur in individuals inhabiting in disease-endemic nations nevertheless too is a problematic issue in a continuous increasing manner among travelers (Wall et al., 2012). According to WHO records in 20 May 2021 and IAMAT records, the current status of leishmaniasis in Iraq is sounding an alarm due to elevated numbers of cases of cutaneous leishmaniasis.

Early diagnosis is crucial for halting rigorous impairment or even mortality of cases (Schallig and Oskam 2002). The diagnostic protocols employed in the identification of Leishmania contagions by the aid of culturing or serological approaches is somewhat a long duty with diminished specificity (Nicolas et al., 2002). On the contrary, since the invention of the first thermal cycler instrument in 1987, molecular approaches have gained much attention in the context of detection of etiological agents in clinical

specimens (Zarlenga and Higgins 2001). In this context, molecular approaches, basically PCR, have become vital tools for the diagnosis of infectious diseases (Bastien et al., 2008).

High levels of sensitivity and specificity, quick identification of the parasite, high reliability, reproducibility, and the likelihood of direct application on clinical specimens obtaining results in a matter of a few hours gain numerous advantages of molecular techniques when compared to conventional ones (Paiva-Cavalcanti et al., 2010).

In this study, eight out of twelve samples were proved to harbor the etiological agent of leishmaniasis. The frequency of occurrence of leishmaniasis in the twelve investigated samples was (8/12= 66.66%) as inferred from Real time-PCR experiment. This would underpin the potential, accuracy, efficacy, reproducibility, reliability, rapidness of the Real time-PCR in detection of leishmaniasis pathogens in the clinical specimen especially in LCL cases. In the light of getting rapid diagnosis for cases of LCL, the real time-PCR method is more superior to the conventional methods (i.e., microscopy and immunodiagnostic methods) that necessitate at least three days to get reliable results. Rapid treatment would reduce the complications of LCL.

The real time –PCR methodology has certain advantages over the conventional PCR. Of most paramount importance are recording the data of each cycle online (at the time of the run). Thus, there is no need to carry out an agarose gel post –PCR to evaluate the success of the PCR. Hence, there is a saving in time, facilities and quickness in getting results (Mortarino et al., 2004; Kubista et al., 2006).

Data obtained in this study greatly underpin the indispensable need for performing a confirmatory diagnostic test beside the clinical manifestations. This is attributed to the misleading information that could be derived from the clinical manifestations. Moreover, LCL manifestations could be like those of leprosy. Thus, applying Real time-PCR would be a crucial in the rapid obvious steps towards better and correct diagnosis of LCL cases.

Real-time PCR is superior to traditional PCR as it is quicker, reduced labor-intensive, low level of contamination, and by employing probes the sensitivity and specificity would be improved (Dymond, 2013, Mohammadiha et al., 2013, Yang and Rothman, 2004). Furthermore, by using standard curves real-time PCR can be used for quantification. As a consequence of the high sensitivity, qPCR can be employed in screening of cases and tracing of the asymptomatic carriers. Thereby the gaps in the context of the exploration of leishmaniasis would be addressed with *Leishmania* (Francino et al., 2006, Mary et al., 2006, Pourabbas et al., 2013).

There exist numerous reports of different variants of PCRs targeting *Leishmania*, by the aid of various molecular targets, nonetheless, the majority of protocols do target a single species (Francino et al., 2006, Srivastava et al., 2011b), a group of closely related species (Harris et al., 1998, Odiwuor et al., 2011), in a non-quantitative manner, Harris et al., 1998, Odiwuor et al., 2011, Srivastava et al., 2011b), and low levels of sensitivity (Wortmann et al., 2005). There are only certain and limited publications addressing the real-time PCR assays that do target all or approximately all of the 20 different *Leishmania* species existed in humans (Castilho et al., 2008, Tupperwar et al., 2008, Wortmann et al., 2001). Several protocols would target multicopy genes (Bossolasco et al., 2003, Francino et al., 2006, Talmi-Frank et al., 2010) and certain protocols for multicopy genes also utilize SYBR Green (de Monbrison et al., 2007). Multicopy genes are frequently favorable to enhance sensitivity.

Conclusion

Real time – PCR is the gold standard solution for diagnostic purposes of leishmaniasis. It is cost-effective, time saving, labor saving, reproducible, and reliable approach. However, the low percentage of occurrence of LCL among the study participants could be attributed to the sample size. Prospective studies would focus on studying the prevalence of LCL among Iraqi patients in much more sample size.

References

- 1- Convit J, Ulrich M, Fernández CT, et al. The clinical and immunological spectrum of American cutaneous leishmaniasis. *Trans R Soc Trop Med Hyg* 1993; 87:444. (Right???)
- 2- Hernan Aviles, Alejandro Belli, Rodrigo Armijos, Fernando P. Monroyt, and Eva Harris. PCR Detection and identification of *Leishmania* parasites in clinical specimens in Ecuador: A comparison with classical diagnostic methods. *J Parasitol.*, 85(2), 1999 p. 181-187. <https://doi.org/10.2307/3285616>. (Right???)
- 3- Vera-Izaguirre D, Vega-Memije E, Quintanilla Cedillo M, et al. : Leishmaniasis revisión. *DCMQ.* 2006;4(4):252–260. (Right???)
- 4- CDC; Centre for Disease Control and Prevention, [:https://www.cdc.gov/parasites/leishmaniasis/gen_info/faqs.html](https://www.cdc.gov/parasites/leishmaniasis/gen_info/faqs.html)). (Right???)
- 5- WHO; World Health Organization; <https://www.who.int/news-room/fact-sheets/detail/leishmaniasis>(Right???)
- 6- Andrade-Narváez FJ, Vargas-González A, Canto-Lara SB, Damián-Centeno AG. Clinical picture of cutaneous leishmaniasis due to *Leishmania (Leishmania) mexicana* in the Yucatan peninsula, Mexico. *Mem Inst Oswaldo Cruz.* 2001 Feb; 96(2):163-7. (Right???)

- 7- Reithinger R, Dujardin JC, Louzir H, Pirmez C, Alexander B, Brooker S. Cutaneous leishmaniasis. *Lancet Infect Dis.* 2007 Sep; 7(9):581-96. . (Right???)
- 8- Edoardo Torres-Guerrero, Marco Romano Quintanilla-Cedillo, Julieta Ruiz-Esmenjaud, Roberto Arenas: Leishmaniasis: a review *F1000Res.* 2017; 6: 750. (Right???)
- 9- Desjeux P. Leishmaniasis. *Nat Rev Microbiol.* 2004 Sep; 2(9):692. (Right???)
- 10- Emma C. Wall, Julie Watson, Margaret Armstrong, Peter L. Chiodini, Diana N. Lockwood. Epidemiology of Imported Cutaneous Leishmaniasis at the Hospital for Tropical Diseases, London, United Kingdom: Use of Polymerase Chain Reaction to Identify the Species. *Am J Trop Med Hyg.* 2012 Jan 1; 86(1): 115–118. (Right???)
- 11- Schallig HD, Oskam L. Molecular biological applications in the diagnosis and control of leishmaniasis and parasite identification. *Trop Med Int Health.* 2002 ;7(8): 641-51. (Right???)
- 12- Nicolas L, Prina E, Lang T, Milon G. Realtime PCR for detection and quantitation of *Leishmania* in mouse tissues. *J Clin Microbiol.* 2002;40(5):1666-9. (Right???)
- 13- Zarlenga DS, Higgins J. PCR as a diagnostic and quantitative technique in veterinary parasitology. *Vet Parasitol.* 2001;101(3-4):215-30. (Right???)
- 14- Bastien P, Procop GW, Reischl U. Quantitative realtime PCR is not more sensitive than conventional PCR. *J Clin Microbiol.* 2008;46(6):1897-900 (Right???)
- 15- Paiva-Cavalcanti M, Regis-da-Silva CG , Gomes YM . Comparison of real-time PCR and conventional PCR for detection of *Leishmania (Leishmania) infantum* infection: a mini-review. *Journal of Venomous Animals and Toxins including Tropical Diseases* ISSN 1678-9199 | 2010 , 16: 537-542 (Right???)
- 16- Mortarino M, Franceschi A, Mancianti F, Bazzocchi C, Genchi C, Bandi C. Quantitative PCR in the diagnosis of *Leishmania*. *Parassitologia.* 2004; 46(1-2):163-7. 11. (Right???)
- 17- Kubista M, Andrade JM, Bengtsson M, Forootan A, Jonák J, et al. The real time polymerase chain reaction. *Mol Aspects Med.* 2006; 27(2-3):95-125. . (Right???)
- 18- J.S. Dymond. Explanatory chapter: quantitative PCR *Methods Enzymol.*, 529 (2013), pp. 279-289 . (Right???)
- 19- S. Yang, R.E. Rothman. PCR-based diagnostics for infectious diseases: uses, limitations, and future applications in acute-care settings *Lancet Infect. Dis.*, 4 (2004), ;4(6):337-48

- 20- A. Mohammadiha, M. Mohebbali, A. Haghighi, R. Mahdian, A.R. Abadi, Z. Zarei, F. Yeganeh, B. Kazemi, N. Taghipour, B. Akhondi Comparison of real-time PCR and conventional PCR with two DNA targets for detection of *Leishmania (Leishmania) infantum* infection in human and dog blood samples *Exp. Parasitol.*, 133 (2013), pp. 89-94
- 21- O. Francino, L. Altet, E. Sanchez-Robert, A. Rodriguez, L. Solano-Gallego, J. Alberola, L. Ferrer, A. Sanchez, X. Roura. Advantages of real-time PCR assay for diagnosis and monitoring of canine leishmaniosis *Vet. Parasitol.*, 137 (2006), pp. 214-221
- 22- C. Mary, F. Faraut, M.P. Drogoul, B. Xeridat, N. Schleinitz, B. Cuisenier, H. Dumon. Reference values for *Leishmania infantum* parasitemia in different clinical presentations: quantitative polymerase chain reaction for therapeutic monitoring and patient follow-up *Am. J. Trop. Med. Hyg.*, 75 (2006), pp. 858- 863
- 23- Bahman Pourabbas, Abdolkarim Ghadimi Moghadam, Gholamreza Pouladfar, Zahra Rezaee, Abdolvahab Alborzi. [Quantification of *Leishmania infantum* Kinetoplast DNA for Monitoring the Response to Meglumine Antimoniote Therapy in Visceral Leishmaniasis](#). *Am J Trop Med Hyg.* 2013 May 1; 88(5): 868–871. doi: 10.4269/ajtmh.12-0440
- 24- Moghadam, G. Pouladfar, Z. Rezaee, A. Alborzi. Quantification of *Leishmania infantum* kinetoplast DNA for monitoring the response to meglumine antimoniate therapy in visceral leishmaniasis. *Am. J. Trop. Med. Hyg.*, 88 (2013), pp. 868-871
- 25- G. Wortmann, C. Sweeney, H.S. Houg, N. Aronson, J. Stiteler, J. Jackson, C. Ockenhouse. Rapid diagnosis of leishmaniasis by fluorogenic polymerase chain reaction. *Am J Trop Med Hyg.* . 2001 Nov;65(5):583-7. doi: 10.4269/ajtmh.2001.65.583.
- 26- T.M. Castilho, L.M. Camargo, D. McMahon-Pratt, J.J. Shaw, L.M. Floeter-Winter. A real-time polymerase chain reaction assay for the identification and quantification of American *Leishmania* species on the basis of glucose-6-phosphate dehydrogenase. *Am. J. Trop. Med. Hyg.*, 78 (2008), pp. 122-132
- 27- E. Harris, G. Kropp, A. Belli, B. Rodriguez, N. Agabian. Single-step multiplex PCR assay for characterization of New World *Leishmania* complexes. *J. Clin. Microbiol.*, 1998; 36(7):1989-95. doi: 10.1128/JCM.36.7.1989-1995.1998.
- 28- S. Ogado Ceasar Odiwuor, A. Ageed Saad, S. de Doncker, I. Maes, T. Laurent, et al.. Universal PCR assays for the differential detection of all Old World species. *European Journal of Clinical*

Microbiology and Infectious Diseases, Springer Verlag, 2010, 30 (2), pp.209-218.
ff10.1007/s10096-010-1071-3ff. fahal00630326f

29- Srivastava P, Mehrotra S, Tiwary P, Chakravarty J, Sundar S (2011) Diagnosis of Indian Visceral Leishmaniasis by Nucleic Acid Detection Using PCR. PLoS ONE 6(4): e19304. <https://doi.org/10.1371/journal.pone.0019304>

30- N. Tupperwar, V. Vineeth, S. Rath, T. Vaidya. Development of a real-time polymerase chain reaction assay for the quantification of Leishmania species and the monitoring of systemic distribution of the pathogen. Diagn. Microbiol. Infect. Dis. 2008 May;61(1):23-30. doi: 10.1016/j.diagmicrobio.2007.12.013.

31- S. Bossolasco, G. Gaiera, D. Olchini, M. Gulletta, L. Martello, A. Bestetti, L. Bossi, L. Germagnoli, A. Lazzarin, C. Uberti-Foppa, P. Cinque. Real-time PCR assay for clinical management of human immunodeficiency virus-infected patients with visceral leishmaniasis. J. Clin. Microbiol. [J Clin Microbiol.](#) 2003 Nov; 41(11): 5080–5084.

33- Talmi-Frank D, Nasereddin A, Schnur LF, Schönian G, Töz SÖ, Jaffe CL, et al. (2010) Detection and Identification of Old World Leishmania by High Resolution Melt Analysis. PLoS Negl Trop Dis 4(1): e581. <https://doi.org/10.1371/journal.pntd.0000581>

34- F. de Monbrison, I. Mihoubi, S. Picot. Real-time PCR assay for the identification of cutaneous Leishmania parasite species in Constantine region of Algeria. Acta Trop. 2007; 102(2):79-83. doi: 10.1016/j.actatropica.2007.04.001.